Clinical trial
SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
NCT00052897 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00052897 |
|---|---|
| Title | SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia |
| Official title | A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Anal Cancer |
| Intervention type | Biological |
| Interventions | HspE7 |
| Enrollment | 18 |
| Start date | Dec 1, 2002 |
| Primary completion | Jul 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: